在慢性阻塞性肺病中,多西里丁有效地杀死抗生素耐药的黄金葡萄球菌
Lianshen Zhang1, Yingzhang Zhang1, Lijie Tian2
1Respiratory and Critical Care Medicine Department, Tongxiang Second People's Hospital, Tongxiang, Zhejiang, China.
Microbiology spectrum
|November 12, 2024
概括
抗癌药物doxifluridine在慢性阻塞性肺病 (COPD) 患者中显示出强大的抗菌作用,对耐药黄金葡萄球菌 (MRSA) 产生强烈的抗菌作用. 这种重新设计的药物有效杀死细菌,减少生物膜,并且是安全的,为新的感染治疗提供了希望.
科学领域:
- 药理学和微生物学 药理学和微生物学
- 药物重用 药物重用
- 抗微生物耐药性 抗微生物耐药性
背景情况:
- 慢性阻塞性肺病 (COPD) 是一个主要的全球健康问题,常常由抗生素耐药细菌的感染复杂化,如甲素耐药黄金葡萄球菌 (MRSA).
- 越来越多的多药耐药 (MDR) 细菌的流行需要开发新的治疗策略,并突出了药物重新利用的潜力.
研究的目的:
- 调查光皮里米丁抗癌药物多克西弗鲁里丁对抗多药耐药黄金葡萄球菌的抗菌潜力.
- 评估多キシ里丁作为治疗MRSA感染的治疗剂的疗效,安全性和协同潜力,特别是在COPD的背景下.
主要方法:
- 使用最小抑制度 (MIC),最小杀菌度 (MBC),生长曲线分析,杀时测试和生物膜测试来评估抗菌活性.
- 通过象棋板测试确定了协同效应.
- 使用血液溶解和细胞毒性试验评估了安全性,并在Galleria mellonella感染模型中测试了体内疗效.
主要成果:
- 杜西里丁对临床MDR黄金菌分离物具有显著的抗菌活性,MIC值为0.52μg/mL,MBC值为14μg/mL.
- 该药物在8小时内表现出强大的杀菌作用,显著降低了细菌生物膜质量和活力,并与其他抗生素产生协同作用.
- 安全性测试证实没有血溶性毒性或细胞毒性,体内研究表明,多西里丁在感染Galleria mellonella幼虫的生存率显著提高.
结论:
- 多キシ里丁在体外和体内表现出对MRSA的有希望的抗菌活性,这表明它有可能作为一种用于治疗COPD患者耐药细菌感染的重定向药物.
- 良好的安全性,快速杀菌作用,生物膜破坏能力和协同作用的潜力使多克西里丁成为进一步临床研究的有力的候选人.
- 这项研究强调了药物重用在解决抗生素耐药性和管理复杂感染的关键挑战的价值,在像COPD患者这样的脆弱患者群体中.
相关概念视频
Pulmonary Tuberculosis V
170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
COPD: Management Using Bronchodilators and Corticosteroids
182
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
182
Combined Effects of Drugs: Synergism
3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.7K
Cystic Fibrosis: Management
143
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
143
Pleural Effusion II: Symptoms and Management
154
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
154


